- Home
- / Pangen Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Pangen Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩4.9 K
2024-10-29
Market Capitalization
₩56 B
2024-10-29
Revenue
₩14.7 B
FY, 2024
CreditSafe Score
?
Score changed on Jul 23, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.7B | 2.9B | 6.2B | 7.9B | 6.5B | 7.3B | 14.7B |
| Cost of goods sold | 2.9B | 1.8B | 1.6B | 3.8B | 2.1B | 4.9B | 8.2B |
| Gross profit | 4.3B | 1.4B | 4.8B | 4.2B | 4.5B | 2.5B | 6.5B |
| Gross profit margin, % | 48.0% | 77.3% | 52.6% | 68.8% | 33.9% | 44.4% | |
| Operating expense total | 5.0B | 7.4B | 6.7B | 6.0B | 7.4B | 5.1B | 4.0B |
| Depreciation and amortization | 847.6M | 1.7B | 1.6B | 1.4B | 1.6B | 1.6B | 1.5B |
| EBITDA | (634.4M) | (6.0B) | (1.9B) | (1.8B) | (2.9B) | (2.6B) | 2.5B |
| EBITDA margin, % | -208.8% | -31.4% | -23.2% | -45.2% | -35.2% | 17.4% | |
| EBIT | (1.5B) | (8.3B) | (3.5B) | (3.2B) | (4.6B) | (4.2B) | 1.1B |
| EBIT margin, % | -286.6% | -56.8% | -40.7% | -70.1% | -57.1% | 7.3% | |
| Interest income | 535.3M | 520.0M | 255.5M | 179.7M | 246.6M | 41.8M | 184.8M |
| Interest expense | 517.0M | 1.2B | 1.0B | 293.3M | 128.8M | 220.7M | 322.1M |
| Pre tax profit | (1.5B) | (8.9B) | (4.4B) | (3.2B) | (4.4B) | (4.4B) | 1.0B |
| Income tax expense | 3.2B | 3.2M | 60.5M | 58.7M | 47.4M | 59.9M | |
| Net Income | (4.6B) | (8.9B) | (4.4B) | (3.3B) | (4.5B) | (4.5B) | 943.7M |